Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10683345
APP PUB NO 20170260265A1
SERIAL NO

15603259

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
HOFFMANN-LA ROCHE INC150 CLOVE ROAD OVERLOOK AT GREAT NOTCH SUITE 8 LITTLE FALLS NJ 07424

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Duerr, Harald Starnberg, DE 23 210
Herting, Frank Penzberg, DE 47 209
Klein, Christian Bonstetten, CH 571 9941
Regula, Joerg Thomas Munich, DE 98 1330
Rueth, Matthias Penzberg, DE 26 214
Stubenrauch, Kay-Gunnar Penzberg, DE 54 506

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 16, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 16, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00